DBC awarded a 2-year Phase I SBIR from NIMH for the measurement of a novel psychiatric drug

DBC has been awarded a 2-year Phase I SBIR from NIH's National Institute of Mental Health (NIMH) for a study comparing DBC's continuous, real-time brain sensors to standard methods used to monitor pharmacokinetics of a new drug. This study will be performed with collaborators Drs. Barb Slusher and Dan O'Connor at the Johns Hopkins Brain Science Institute (BSi). The results are expected to demonstrate the benefits to drug discovery of DBC's aptamer-based biosensors in the brain used in conjunction with neural recordings.